New drugs powered Pfizer Inc.’s fourth-quarter sales, a sign the drugmaker’s effort to remake itself as a smaller company relying on its own laboratories for growth is starting to emerge. Sales of the New York-based company’s patent-protected medicines rose 7% to $10.5 billion. Among the products notching big gains were blood-thinner Eliquis, which posted a 21% increase in quarterly sales to $1.1 billion, and breast-cancer therapy Ibrance, whose sales increased 13% to $1.3 billion. Newly approved rare-disease drug Vyndaqel...

Source: Wall Street Journal January 28, 2020 12:44 UTC